-
Mashup Score: 3Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows - 1 year(s) ago
A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remission in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4JNCCN 360 - CLL - BTK Inhibitors for CLL: International Consensus for Managing Cardiovascular Risk - 2 year(s) ago
By: Joshua Swore, PhD Posted: Thursday, September 15, 2022 Because of the growing concern about the cardiovascular risks associated with Bruton’s tyrosine kinase (BTK) inhibitors—specifically, ibrutinib—a panel of international experts in chronic lymphocytic leukemia (CLL) have published a set of evidence-based…
Source: jnccn360.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JNCCN: BTK Inhibitors for #CLL: International Consensus for Managing Cardiovascular Risk: https://t.co/yIplV62e0h #JNCCN360 #leusm #CLL…
-
BTK Inhibitors for #CLL: International Consensus for Managing Cardiovascular Risk: https://t.co/yIplV62e0h #JNCCN360 #leusm #CLLsm #ChronicLymphocyticLeukemia #GlobOnc #CardioOnc https://t.co/9afqu7r2by
-
-
Mashup Score: 1
By: Lauren Harrison, MD, MS Posted: Wednesday, September 7, 2022 Researchers from Nanjing Medical University in China described the oncogenic role of p21-activted kinase 1 (PAK1) in the progression of chronic lymphocytic leukemia (CLL) and development of resistance to the kinase inhibitor ibrutinib. Hui Jin, PhD, and…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read About Defining the Role of #PAK1 in Ibrutinib-Resistant #CLL on #JNCCN360: https://t.co/pcwfZLeELS #leusm #ChronicLymphocyticLeukemia https://t.co/onTqlRZaXH
-
-
Mashup Score: 1JNCCN 360 - CLL - Ibrutinib Treatment in CLL: Focus on Disease With and Without Deletion 17p - 2 year(s) ago
By: Joshua Swore Posted: Tuesday, August 23, 2022 According to a study published in Haematologica, patients with deletion 17p chronic lymphocytic leukemia (CLL) have a poor prognosis compared with patients without the deletion. “While [Bruton’s tyrosine kinase] inhibitors are currently considered a standard of care for…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ibrutinib Treatment in #CLL: Focus on Disease With and Without Deletion 17p: https://t.co/DckUs7nP4f #JNCCN360 #leusm #ChronicLymphocyticLeukemia #CLLsm https://t.co/WZkJnvKcEj
-
-
Mashup Score: 2JNCCN 360 - CLL - Long-Term Outcomes With Chemoimmunotherapy Regimen in IGHV-Mutated CLL - 2 year(s) ago
By: Julia Fiederlein Posted: Tuesday, August 9, 2022 Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues conducted a phase II trial to investigate the role of ibrutinib plus fludarabine, cyclophosphamide, and obinutuzumab (FCG) in previously untreated patients with IGHV-mutated…
Source: jnccn360.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JNCCN: Long-Term Outcomes With #Chemoimmunotherapy Regimen in IGHV-Mutated #CLL: https://t.co/twgEcqPReL #JNCCN360 #immunotherapy #leu…
-
Long-Term Outcomes With #Chemoimmunotherapy Regimen in IGHV-Mutated #CLL: https://t.co/twgEcqPReL #JNCCN360 #immunotherapy #leukemia #leusm #CLLsm #chroniclymphocyticleukemia https://t.co/PnxMrIRlQq
-
-
Mashup Score: 0Immune Response Muted in Patients With NHL/CLL Who Are Vaccinated Against COVID-19 | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Skip Nav Destination July 26, 2022 Because patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), a subtype of NHL, have both a higher risk of poor outcomes from COVID-19 and immune system defects as a result of their…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A recent study finds that antibody binding and neutralization against the original #SARSCoV2 virus and its variants was substantially lower in patients with #nonHodgkin #lymphoma (#NHL) and #ChronicLymphocyticLeukemia (#CLL) compared to healthy vaccinees https://t.co/MzeJHiy8zn
-
-
Mashup Score: 3
Pentraxin-related protein 3 (PTX3), commonly produced by myeloid and endothelial cells, is a humoral pattern recognition protein of the innate immune system. Because PTX3 plasma levels of patients with chronic lymphocytic leukemia (CLL) are high and most circulating cells in patients with CLL are
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
#PTX3 provides a survival advantage to #ChronicLymphocyticLeukemia cells| from Zeev Estrov @MDAndersonNews @TelAvivUni |#ReadTheJI #cancer #CLL 👉 https://t.co/0dv7qmdGdb https://t.co/mJrF7KVMvz
-
-
Mashup Score: 1Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia - 2 year(s) ago
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Among fit patients with previously untreated #chronicLymphocyticLeukemia, fixed-duration venetoclax plus obinutuzumab, without/with ibrutinib, yields superior PFS rates to standard chemoimmunotherapy. Presented at @EHA_Hematology conference #EHA2022. https://t.co/wL6FTYfllb #CLL
-
-
Mashup Score: 1VJHemOnc – The video journal of hematological oncology - 2 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨Day 1 at #ASCO22 and we’re excited to be talking with Kerry Rogers (@OhioState) on key updates in #CLL including how to manage BTK class-driven events Stay up to date at https://t.co/O9p0vDBrzw #ChronicLymphocyticLeukemia #CLLsm #Leusm https://t.co/Vc1MbddSQn
-
-
Mashup Score: 0
ACP and EBSCO Health collaborated to provide our members free access to the most current, evidence-based clinical information resource, DynaMed®. Access it here!
Source: www.acponline.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#IrritableBowelSyndrome, #ChronicLymphocyticLeukemia, #Constipation in Adults, updated on #DynaMed with ACP input https://t.co/NMzJ7DHQnf. In collaboration with @EBSCO_Health ACP members have free access to DynaMed, an evidence-based clinical decision support tool, until 2023. https://t.co/FAjt5jvgnw
-
Three-drug combination therapy effective in patients with high-risk #chroniclymphocyticleukemia, trial shows @danafarber https://t.co/Z5q4zS1Vvl